Jappe Uta
Forschungsgruppe Klinische und Molekulare Allergologie, Forschungszentrum Borstel, Parkallee 35, 23845, Borstel, Deutschland.
Interdisziplinäre Allergieambulanz, Medizinische Klinik III, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Deutschland.
Hautarzt. 2017 Apr;68(4):271-281. doi: 10.1007/s00105-017-3958-8.
Allergen-specific immunotherapy (SIT) does not achieve 100% efficacy, nor is there a reliable marker for therapy failure. However, advances in molecular allergology over the past few years have allowed a significantly improved characterization of the patients using molecular-allergological analysis methods (molecular phenotyping). Thus, major and minor allergens can be identified. In addition, the marker allergens for the severity of an allergic reaction, the pathological and therapeutic predictive marker allergens, and sensitization patterns are identified.
变应原特异性免疫疗法(SIT)并未达到100%的疗效,也没有可靠的治疗失败标志物。然而,过去几年分子变应原学的进展使得使用分子变应原学分析方法(分子表型分析)对患者进行显著改善的特征描述成为可能。因此,可以识别主要和次要变应原。此外,还可以识别过敏反应严重程度的标志物变应原、病理和治疗预测标志物变应原以及致敏模式。